Boehringer Ingelheim’s team created a highly efficient 3-step synthesis ... score of 72 percent, and a top-tier innovation Green Aspiration Level (iGAL). Scalable to meet increasing demand, learn how ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

While you may think of healthcare as only covering human health, animal and pet health is also a growing sector. Click to ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Program, a national youth initiative of the Canadian Cattle Association (CCA), has announced its 16 finalists for ...

Summary: VDS, one of the most influential international technology events, announces an impressive speaker lineup and agenda ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens ... which include Sanofi, Boehringer Ingelheim and Pfizer. In its latest statement ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the Wegovy formulation for obesity got the green light from the NMPA last month.

In order to acquire the rights to a preclinical cancer program, Boehringer Ingelheim has teamed up with Circle Pharma, an undruggable target expert, and put up a package that might be worth up to ...